Evaluation of the Clinical Systems for Polymyxin Susceptibility Testing of Clinical Gram-Negative Bacteria in China

ObjectivesThe performance of mainstream commercial antimicrobial susceptibility testing systems on polymyxins has not been well evaluated in China. In this study, three antimicrobial susceptibility testing systems were evaluated for polymyxin B and colistin.MethodsThe MICs of 257 Gram-negative strai...

Full description

Bibliographic Details
Main Authors: Ying Zhu, Peiyao Jia, Menglan Zhou, Jingjia Zhang, Ge Zhang, Wei Kang, Simeng Duan, Tong Wang, Yingchun Xu, Qiwen Yang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Microbiology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fmicb.2020.610604/full
id doaj-83d4145f02c643baa25ff86ed261ebd2
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Ying Zhu
Ying Zhu
Peiyao Jia
Peiyao Jia
Menglan Zhou
Jingjia Zhang
Ge Zhang
Wei Kang
Simeng Duan
Tong Wang
Yingchun Xu
Qiwen Yang
spellingShingle Ying Zhu
Ying Zhu
Peiyao Jia
Peiyao Jia
Menglan Zhou
Jingjia Zhang
Ge Zhang
Wei Kang
Simeng Duan
Tong Wang
Yingchun Xu
Qiwen Yang
Evaluation of the Clinical Systems for Polymyxin Susceptibility Testing of Clinical Gram-Negative Bacteria in China
Frontiers in Microbiology
antimicrobial susceptibility testing
polymyxin
essential agreement
category agreement
very major error
major error
author_facet Ying Zhu
Ying Zhu
Peiyao Jia
Peiyao Jia
Menglan Zhou
Jingjia Zhang
Ge Zhang
Wei Kang
Simeng Duan
Tong Wang
Yingchun Xu
Qiwen Yang
author_sort Ying Zhu
title Evaluation of the Clinical Systems for Polymyxin Susceptibility Testing of Clinical Gram-Negative Bacteria in China
title_short Evaluation of the Clinical Systems for Polymyxin Susceptibility Testing of Clinical Gram-Negative Bacteria in China
title_full Evaluation of the Clinical Systems for Polymyxin Susceptibility Testing of Clinical Gram-Negative Bacteria in China
title_fullStr Evaluation of the Clinical Systems for Polymyxin Susceptibility Testing of Clinical Gram-Negative Bacteria in China
title_full_unstemmed Evaluation of the Clinical Systems for Polymyxin Susceptibility Testing of Clinical Gram-Negative Bacteria in China
title_sort evaluation of the clinical systems for polymyxin susceptibility testing of clinical gram-negative bacteria in china
publisher Frontiers Media S.A.
series Frontiers in Microbiology
issn 1664-302X
publishDate 2021-02-01
description ObjectivesThe performance of mainstream commercial antimicrobial susceptibility testing systems on polymyxins has not been well evaluated in China. In this study, three antimicrobial susceptibility testing systems were evaluated for polymyxin B and colistin.MethodsThe MICs of 257 Gram-negative strains collected from clinical cases and livestock were determined and analyzed. Using Broth Microdilution as the gold standard, the performance of VITEK 2® COMPACT, PhoenixTM M50, and Bio-kont AST System were evaluated. Essential agreement (EA), category agreement (CA), very major error (VME), and major error (ME) were calculated for comparison. The results of mcr-1 positive strains were separately discussed.ResultsThe EA, CA, VME, and ME to polymyxin B for Bio-kont were 83.5, 95.6, 13.1, and 0.6%, respectively. The EAs, CAs, VMEs, and MEs to colistin were as follows: Bio-kont, 86.7%/96.5%/7.2%/1.7%; Vitek 2, 64.2%/86.8%/41.0%/0%, and Phoenix M50, 92.9%/92.9%/21.7%/0%. The performance of Bio-kont to polymyxin B and colistin for Pseudomonas spp. (EA, CA < 90%, VME > 1.5%, ME = 5.6%/10%) and Enterobacter spp. (EA, CA < 90%, VME > 1.5% and ME = 0%), Vitek to colistin for most genera, and Phoenix to colistin for Enterobacter spp. (EA, CA < 90%, VME > 1.5%, ME = 0%) were unsatisfactory compared with other genera. The performance of Bio-kont to polymyxins for Escherichia spp. and Phoenix to colistin for Citrobacter spp., Escherichia spp., and Klebsiella spp., which all met the CLSI standard, were satisfactory. When the susceptibility of mcr-1 positive E. coli was tested, Bio-kont and Phoenix M50 presented excellent performance with no category errors, while Vitek 2 performed a high VME (25.5%).ConclusionWith relatively more accurate results for polymyxin B and colistin and lower VME, Bio-kont has an advantage in polymyxin antimicrobial susceptibility testing, especially for Escherichia spp., Klebsiella spp., Citrobacter spp. and Acinetobacter spp.
topic antimicrobial susceptibility testing
polymyxin
essential agreement
category agreement
very major error
major error
url https://www.frontiersin.org/articles/10.3389/fmicb.2020.610604/full
work_keys_str_mv AT yingzhu evaluationoftheclinicalsystemsforpolymyxinsusceptibilitytestingofclinicalgramnegativebacteriainchina
AT yingzhu evaluationoftheclinicalsystemsforpolymyxinsusceptibilitytestingofclinicalgramnegativebacteriainchina
AT peiyaojia evaluationoftheclinicalsystemsforpolymyxinsusceptibilitytestingofclinicalgramnegativebacteriainchina
AT peiyaojia evaluationoftheclinicalsystemsforpolymyxinsusceptibilitytestingofclinicalgramnegativebacteriainchina
AT menglanzhou evaluationoftheclinicalsystemsforpolymyxinsusceptibilitytestingofclinicalgramnegativebacteriainchina
AT jingjiazhang evaluationoftheclinicalsystemsforpolymyxinsusceptibilitytestingofclinicalgramnegativebacteriainchina
AT gezhang evaluationoftheclinicalsystemsforpolymyxinsusceptibilitytestingofclinicalgramnegativebacteriainchina
AT weikang evaluationoftheclinicalsystemsforpolymyxinsusceptibilitytestingofclinicalgramnegativebacteriainchina
AT simengduan evaluationoftheclinicalsystemsforpolymyxinsusceptibilitytestingofclinicalgramnegativebacteriainchina
AT tongwang evaluationoftheclinicalsystemsforpolymyxinsusceptibilitytestingofclinicalgramnegativebacteriainchina
AT yingchunxu evaluationoftheclinicalsystemsforpolymyxinsusceptibilitytestingofclinicalgramnegativebacteriainchina
AT qiwenyang evaluationoftheclinicalsystemsforpolymyxinsusceptibilitytestingofclinicalgramnegativebacteriainchina
_version_ 1724257024091357184
spelling doaj-83d4145f02c643baa25ff86ed261ebd22021-02-22T05:22:54ZengFrontiers Media S.A.Frontiers in Microbiology1664-302X2021-02-011110.3389/fmicb.2020.610604610604Evaluation of the Clinical Systems for Polymyxin Susceptibility Testing of Clinical Gram-Negative Bacteria in ChinaYing Zhu0Ying Zhu1Peiyao Jia2Peiyao Jia3Menglan Zhou4Jingjia Zhang5Ge Zhang6Wei Kang7Simeng Duan8Tong Wang9Yingchun Xu10Qiwen Yang11Department of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, ChinaGraduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, ChinaDepartment of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, ChinaGraduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, ChinaDepartment of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, ChinaDepartment of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, ChinaDepartment of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, ChinaDepartment of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, ChinaDepartment of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, ChinaDepartment of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, ChinaDepartment of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, ChinaDepartment of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, ChinaObjectivesThe performance of mainstream commercial antimicrobial susceptibility testing systems on polymyxins has not been well evaluated in China. In this study, three antimicrobial susceptibility testing systems were evaluated for polymyxin B and colistin.MethodsThe MICs of 257 Gram-negative strains collected from clinical cases and livestock were determined and analyzed. Using Broth Microdilution as the gold standard, the performance of VITEK 2® COMPACT, PhoenixTM M50, and Bio-kont AST System were evaluated. Essential agreement (EA), category agreement (CA), very major error (VME), and major error (ME) were calculated for comparison. The results of mcr-1 positive strains were separately discussed.ResultsThe EA, CA, VME, and ME to polymyxin B for Bio-kont were 83.5, 95.6, 13.1, and 0.6%, respectively. The EAs, CAs, VMEs, and MEs to colistin were as follows: Bio-kont, 86.7%/96.5%/7.2%/1.7%; Vitek 2, 64.2%/86.8%/41.0%/0%, and Phoenix M50, 92.9%/92.9%/21.7%/0%. The performance of Bio-kont to polymyxin B and colistin for Pseudomonas spp. (EA, CA < 90%, VME > 1.5%, ME = 5.6%/10%) and Enterobacter spp. (EA, CA < 90%, VME > 1.5% and ME = 0%), Vitek to colistin for most genera, and Phoenix to colistin for Enterobacter spp. (EA, CA < 90%, VME > 1.5%, ME = 0%) were unsatisfactory compared with other genera. The performance of Bio-kont to polymyxins for Escherichia spp. and Phoenix to colistin for Citrobacter spp., Escherichia spp., and Klebsiella spp., which all met the CLSI standard, were satisfactory. When the susceptibility of mcr-1 positive E. coli was tested, Bio-kont and Phoenix M50 presented excellent performance with no category errors, while Vitek 2 performed a high VME (25.5%).ConclusionWith relatively more accurate results for polymyxin B and colistin and lower VME, Bio-kont has an advantage in polymyxin antimicrobial susceptibility testing, especially for Escherichia spp., Klebsiella spp., Citrobacter spp. and Acinetobacter spp.https://www.frontiersin.org/articles/10.3389/fmicb.2020.610604/fullantimicrobial susceptibility testingpolymyxinessential agreementcategory agreementvery major errormajor error